[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-001", "question": "A 56-year-old man with long-standing type 2 diabetes, CKD stage 3b, and prior NSTEMI presents for routine follow-up. Medications: metformin 500 mg BID, empagliflozin 10 mg daily, lisinopril 20 mg daily, metoprolol succinate 100 mg daily, and high-intensity statin. BP is 118/66 mm Hg, BMI 31 kg/m², A1c 7.2%. eGFR is 37 mL/min/1.73 m², urinary ACR 620 mg/g (persistent over 9 months), potassium 4.6 mEq/L. He has no hyperkalemia history. Which change in therapy is most appropriate to further reduce his cardiorenal risk?", "options": ["Increase empagliflozin to 25 mg daily", "Add finerenone with close potassium monitoring", "Replace lisinopril with sacubitril/valsartan", "Add basal insulin to target A1c <6.5%", "Add a non-dihydropyridine calcium channel blocker"], "answer": "B", "answer_index": 1, "explanation": "Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces CV events and CKD progression in diabetics with albuminuric CKD already on ACEi/ARB and SGLT2i and with eGFR >25 and K<4.8. Increasing SGLT2 dose adds minimal incremental renal protection, sacubitril/valsartan is not indicated without HFrEF, tighter glycemic control adds little cardiorenal benefit with more risk, and non-DHP CCBs do not provide proven outcome benefit here.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 56-year-old man with T2DM, CKD 3b (eGFR 37), persistent albuminuria (ACR 620 mg/g), prior NSTEMI, already on ACEi, SGLT2i, and statin. Key discriminating findings: eGFR 37, ACR 620 mg/g persistent >3 months, K 4.6, no hyperkalemia history, already on guideline-directed medical therapy (RAAS inhibitor + SGLT2i). The question asks for additional cardiorenal risk reduction. Option B (finerenone) is correct per FIDELIO-DKD/FIGARO-DKD trials showing CV and renal benefits in T2DM with CKD and albuminuria on background RAAS/SGLT2i therapy when eGFR >25 and K <4.8. Option A: dose escalation of empagliflozin provides minimal additional benefit. Option C: sacubitril/valsartan requires HFrEF indication, not present. Option D: intensive glycemic control (A1c already 7.2%) adds minimal cardiorenal benefit with hypoglycemia risk. Option E: non-DHP CCBs lack proven cardiorenal outcome benefit in this context. The item is logically valid with one defensible best answer matching the key. Medical accuracy is excellent, reflecting current 2023-2024 guidelines for diabetic CKD management. Minimal fix: none needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 56-year-old man with T2DM, CKD 3b (eGFR 37), persistent albuminuria (ACR 620 mg/g), prior NSTEMI, already on ACEi, SGLT2i, and statin. Key discriminating findings: eGFR 37, ACR 620 mg/g persistent >3 months, K 4.6, no hyperkalemia history, already on guideline-directed medical therapy (RAAS inhibitor + SGLT2i). The question asks for additional cardiorenal risk reduction. Option B (finerenone) is correct per FIDELIO-DKD/FIGARO-DKD trials showing CV and renal benefits in T2DM with CKD and albuminuria on background RAAS/SGLT2i therapy when eGFR >25 and K <4.8. Option A: dose escalation of empagliflozin provides minimal additional benefit. Option C: sacubitril/valsartan requires HFrEF indication, not present. Option D: intensive glycemic control (A1c already 7.2%) adds minimal cardiorenal benefit with hypoglycemia risk. Option E: non-DHP CCBs lack proven cardiorenal outcome benefit in this context. The item is logically valid with one defensible best answer matching the key. Medical accuracy is excellent, reflecting current 2023-2024 guidelines for diabetic CKD management. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-002", "question": "A 4-year-old boy is brought to the ED with 2 days of fever, abdominal pain, and vomiting. PMH includes Kawasaki disease at 11 months treated with IVIG and aspirin; echocardiography then showed a 7-mm giant aneurysm of the left anterior descending coronary artery, which has since regressed to normal dimensions by age 3. He is off antiplatelets and asymptomatic at baseline. Current vitals: T 39.2°C, HR 145/min, BP 82/48 mm Hg, RR 30/min, SpO2 95% RA. He appears ill and mottled with cool extremities. ECG shows sinus tachycardia with ST-segment depression in V4-V6. High-sensitivity troponin is mildly elevated. Bedside echo shows mild global LV dysfunction (EF 45%), no visible aneurysm. After fluid resuscitation and initiation of broad-spectrum antibiotics, which management step is most appropriate now?", "options": ["Re-treat with high-dose IVIG and start high-dose aspirin", "Obtain emergent coronary CT angiography and start IV heparin", "Start IV milrinone and low-dose aspirin without additional imaging", "Start IV methylprednisolone plus IVIG and transfer for ECMO standby", "Begin norepinephrine for septic shock and defer cardiac-specific therapy"], "answer": "B", "answer_index": 1, "explanation": "Children with prior giant Kawasaki aneurysms remain at risk for thrombosis and stenosis despite angiographic regression; acute coronary syndrome can mimic sepsis. ST depression, hypotension, and troponin elevation warrant urgent coronary imaging (CT angiography) and antithrombotic therapy. Routine retreatment with IVIG is not indicated years later, steroids/ECMO are premature without refractory shock, and treating as isolated sepsis risks missing coronary occlusion.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 4-year-old with prior giant Kawasaki aneurysm (regressed by imaging but still high-risk) presenting with fever, shock physiology, and critical cardiac findings: ST depression V4-V6, elevated troponin, and reduced EF 45%. Key discriminating clues are the Kawasaki history with giant aneurysm (persistent thrombosis/stenosis risk despite regression), acute cardiac ischemia markers (ST changes, troponin), and shock that could be cardiogenic mimicking sepsis. The keyed answer B (emergent coronary CT angiography + IV heparin) correctly prioritizes ruling out acute coronary syndrome/thrombosis in a high-risk patient while initiating antithrombotic therapy. Option A (IVIG re-treatment) addresses acute Kawasaki recurrence but ignores immediate ischemia; C defers imaging despite clear ACS signs; D (steroids/ECMO) is premature without refractory shock; E treats as pure sepsis, risking missed coronary occlusion. The item is logically valid: one best answer is defensible given the high-risk coronary history plus acute ischemic findings. Medical accuracy is strong: giant aneurysms carry persistent thrombotic risk, and urgent coronary imaging with anticoagulation is standard for suspected pediatric ACS in this context. No significant inaccuracies detected. Minimal fix: none needed; item is well-constructed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 4-year-old with prior giant Kawasaki aneurysm (regressed by imaging but still high-risk) presenting with fever, shock physiology, and critical cardiac findings: ST depression V4-V6, elevated troponin, and reduced EF 45%. Key discriminating clues are the Kawasaki history with giant aneurysm (persistent thrombosis/stenosis risk despite regression), acute cardiac ischemia markers (ST changes, troponin), and shock that could be cardiogenic mimicking sepsis. The keyed answer B (emergent coronary CT angiography + IV heparin) correctly prioritizes ruling out acute coronary syndrome/thrombosis in a high-risk patient while initiating antithrombotic therapy. Option A (IVIG re-treatment) addresses acute Kawasaki recurrence but ignores immediate ischemia; C defers imaging despite clear ACS signs; D (steroids/ECMO) is premature without refractory shock; E treats as pure sepsis, risking missed coronary occlusion. The item is logically valid: one best answer is defensible given the high-risk coronary history plus acute ischemic findings. Medical accuracy is strong: giant aneurysms carry persistent thrombotic risk, and urgent coronary imaging with anticoagulation is standard for suspected pediatric ACS in this context. No significant inaccuracies detected. Minimal fix: none needed; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-003", "question": "A 32-year-old woman presents with 3 weeks of migratory polyarthritis, pleuritic chest pain, and low-grade fever. Exam: malar rash sparing nasolabial folds, small bilateral pleural effusions, and mild synovitis of wrists and MCPs. Labs: Hb 10.4 g/dL, platelets 145,000/µL, WBC 3,200/µL, Cr 0.8 mg/dL, urine protein/Cr ratio 0.2, AST/ALT mildly elevated. ESR 75 mm/h, CRP 2.1 mg/dL. ANA 1:640 homogeneous, anti-dsDNA high, low C3/C4. Anti-phospholipid antibodies are negative on two occasions 12 weeks apart. Echocardiogram shows a small pericardial effusion without tamponade. She has a confirmed positive pregnancy test at 6 weeks gestation. Which of the following is the most appropriate initial treatment strategy?", "options": ["Start high-dose prednisone plus mycophenolate mofetil", "Start hydroxychloroquine and low-moderate dose prednisone", "Start methotrexate and high-dose NSAIDs", "Defer immunosuppression and treat with low-dose aspirin alone", "Start belimumab and discontinue hydroxychloroquine once controlled"], "answer": "B", "answer_index": 1, "explanation": "This is new-onset SLE with non-organ-threatening disease in early pregnancy; hydroxychloroquine is recommended in all pregnant SLE patients and improves maternal and fetal outcomes. Low-moderate dose prednisone addresses serositis and arthritis with acceptable fetal safety. Mycophenolate and methotrexate are teratogenic, aspirin alone is inadequate for active disease, and belimumab is not first-line in new, non-severe SLE in pregnancy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 32-year-old woman at 6 weeks gestation presenting with new-onset SLE meeting classification criteria (malar rash, serositis, arthritis, cytopenias, positive ANA, anti-dsDNA, low complement). Key discriminating findings: (1) active but non-organ-threatening disease (no nephritis with protein/Cr 0.2, no CNS involvement, stable Cr), (2) early pregnancy requiring teratogen avoidance, (3) serositis and arthritis needing treatment. Option B (hydroxychloroquine + low-moderate prednisone) is correct: HCQ is recommended for all pregnant SLE patients (improves outcomes, safe in pregnancy) and prednisone addresses active manifestations with acceptable fetal safety profile. Option A: mycophenolate is teratogenic (FDA category D, causes fetal malformations). Option C: methotrexate is absolutely contraindicated in pregnancy (teratogenic, abortifacient); high-dose NSAIDs problematic in pregnancy. Option D: aspirin alone inadequate for active inflammatory disease with serositis/arthritis. Option E: belimumab not first-line for new SLE in pregnancy; limited pregnancy safety data. Medical accuracy: Fully consistent with current ACR/EULAR guidelines and pregnancy management standards. No logical flaws or missing critical details. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 32-year-old woman at 6 weeks gestation presenting with new-onset SLE meeting classification criteria (malar rash, serositis, arthritis, cytopenias, positive ANA, anti-dsDNA, low complement). Key discriminating findings: (1) active but non-organ-threatening disease (no nephritis with protein/Cr 0.2, no CNS involvement, stable Cr), (2) early pregnancy requiring teratogen avoidance, (3) serositis and arthritis needing treatment. Option B (hydroxychloroquine + low-moderate prednisone) is correct: HCQ is recommended for all pregnant SLE patients (improves outcomes, safe in pregnancy) and prednisone addresses active manifestations with acceptable fetal safety profile. Option A: mycophenolate is teratogenic (FDA category D, causes fetal malformations). Option C: methotrexate is absolutely contraindicated in pregnancy (teratogenic, abortifacient); high-dose NSAIDs problematic in pregnancy. Option D: aspirin alone inadequate for active inflammatory disease with serositis/arthritis. Option E: belimumab not first-line for new SLE in pregnancy; limited pregnancy safety data. Medical accuracy: Fully consistent with current ACR/EULAR guidelines and pregnancy management standards. No logical flaws or missing critical details. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-004", "question": "A 61-year-old man with obesity and hypertension presents with exertional dyspnea and occasional chest tightness. Resting ECG is normal. Transthoracic echocardiogram shows EF 60%, mild concentric LVH, and no valvular disease. He undergoes a standard exercise treadmill test using Bruce protocol. At stage 3, he develops 2-mm horizontal ST depression in leads V4-V6 and II, III, aVF with peak HR 142/min (89% of predicted). He has no chest pain and BP rises appropriately. Nuclear perfusion imaging done concurrently shows normal perfusion and normal LV function at rest and stress. Coronary CT angiography reveals a short left main with separate LAD and LCx ostia, no atherosclerotic plaque, and a myocardial bridge in the mid-LAD with 80% systolic compression but preserved diastolic lumen. Which is the best next step in management?", "options": ["Start high-dose beta-blocker therapy and avoid further ischemic workup", "Refer for percutaneous coronary intervention with stenting of the bridged segment", "Order invasive coronary angiography with pressure-wire assessment during dobutamine stress", "Schedule surgical myotomy of the myocardial bridge", "Reassure the patient and no further follow-up is required"], "answer": "C", "answer_index": 2, "explanation": "The discordance between ischemic ST changes and normal perfusion imaging in the setting of a significant myocardial bridge raises concern for dynamic flow limitation, especially at higher heart rates not reached on standard testing. Invasive angiography with physiologic assessment (FFR/iFR or diastolic FFR during inotropic stress) clarifies hemodynamic significance and guides need for intensified medical or surgical therapy. Empiric high-dose beta-blockers or surgery without confirming significance is premature, and PCI in bridged segments has high complication rates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The vignette presents a 61-year-old man with exertional symptoms, ischemic ST changes on ETT (2-mm horizontal ST depression), but normal nuclear perfusion imaging and an 80% systolic myocardial bridge compression. The core issue is discordance between electrical (ST changes) and perfusion findings. Key stem clues: ST depression at 89% max HR, normal perfusion at stress, significant systolic bridge compression but preserved diastolic flow. The question asks for best next step when functional significance remains uncertain. Option C (invasive angiography with pressure-wire assessment during dobutamine) is defensible for physiologic confirmation. However, Option A (high-dose beta-blocker) is equally defensible given: (1) normal perfusion imaging argues against flow-limiting disease, (2) myocardial bridges typically respond to beta-blockers as first-line therapy, (3) the patient is asymptomatic during testing, and (4) invasive testing with dobutamine provocation carries risk without clear indication when perfusion is normal. The stem doesn't specify whether symptoms correlate with ST changes or their severity/frequency, making it unclear whether aggressive invasive workup is warranted over conservative medical management. Medical accuracy: The rationale correctly notes PCI risks in bridges, but dismissing empiric beta-blockers as 'premature' when they're standard first-line therapy is questionable. Minimal fix: Specify that symptoms are severe/limiting despite medical therapy, or that perfusion defects were present, to justify invasive assessment over medical management.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The vignette presents a 61-year-old man with exertional symptoms, ischemic ST changes on ETT (2-mm horizontal ST depression), but normal nuclear perfusion imaging and an 80% systolic myocardial bridge compression. The core issue is discordance between electrical (ST changes) and perfusion findings. Key stem clues: ST depression at 89% max HR, normal perfusion at stress, significant systolic bridge compression but preserved diastolic flow. The question asks for best next step when functional significance remains uncertain. Option C (invasive angiography with pressure-wire assessment during dobutamine) is defensible for physiologic confirmation. However, Option A (high-dose beta-blocker) is equally defensible given: (1) normal perfusion imaging argues against flow-limiting disease, (2) myocardial bridges typically respond to beta-blockers as first-line therapy, (3) the patient is asymptomatic during testing, and (4) invasive testing with dobutamine provocation carries risk without clear indication when perfusion is normal. The stem doesn't specify whether symptoms correlate with ST changes or their severity/frequency, making it unclear whether aggressive invasive workup is warranted over conservative medical management. Medical accuracy: The rationale correctly notes PCI risks in bridges, but dismissing empiric beta-blockers as 'premature' when they're standard first-line therapy is questionable. Minimal fix: Specify that symptoms are severe/limiting despite medical therapy, or that perfusion defects were present, to justify invasive assessment over medical management.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-005", "question": "A 28-year-old woman at 36 weeks gestation presents to the ED with severe headache, visual blurring, and nausea. BP is 188/118 mm Hg, HR 96/min. She is agitated and reports seeing flashing lights. Reflexes are brisk with 3+ patellar reflexes and 1-2 beats of clonus. Labs: platelets 102,000/µL, AST 105 U/L, ALT 98 U/L, Cr 1.2 mg/dL, urine protein/Cr ratio 1.0. Shortly after arrival, she has a generalized tonic-clonic seizure lasting 90 seconds, then becomes postictal. Oxygen saturation is 95% on 2 L nasal cannula. Fetal heart monitoring is reassuring. She has already received a 4-g IV loading dose of magnesium sulfate en route. Which is the most appropriate immediate next step after stabilizing airway and breathing?", "options": ["Administer an additional 2-g IV magnesium bolus and start IV labetalol", "Start continuous propofol infusion and emergent head CT before antihypertensives", "Give IV levetiracetam, discontinue magnesium, and proceed to emergent cesarean delivery", "Start nicardipine infusion targeting BP <120/80 mm Hg and delay delivery for 48 hours", "Administer IV diazepam and begin oral labetalol once she awakens"], "answer": "A", "answer_index": 0, "explanation": "She has eclampsia with severe features; magnesium is first-line for seizure control and recurrence prevention, and a repeat bolus is appropriate after a breakthrough seizure on therapy. Rapid parenteral antihypertensive (e.g., IV labetalol) is needed to control severe BP, with expeditious delivery once stabilized. Propofol, levetiracetam alone, aggressive BP lowering to normal, or delaying delivery are not appropriate initial strategies.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 36-week pregnant woman with eclampsia (seizure in setting of preeclampsia with severe features: BP 188/118, proteinuria, thrombocytopenia, elevated transaminases, hyperreflexia with clonus, visual symptoms). Key discriminating findings: breakthrough generalized tonic-clonic seizure despite 4-g magnesium loading dose, severe hypertension (188/118), and reassuring fetal status post-seizure. The clinical problem is managing eclampsia with breakthrough seizure and severe hypertension after initial magnesium. Option A correctly provides additional 2-g magnesium bolus (standard for breakthrough seizure on magnesium therapy) plus IV labetalol for acute severe hypertension control, aligning with ACOG guidelines. Option B (propofol, delay antihypertensives) inappropriately prioritizes neuroimaging over BP control. Option C incorrectly discontinues magnesium (first-line for eclampsia) and rushes to delivery before stabilization. Option D targets excessively low BP and inappropriately delays delivery 48 hours. Option E uses suboptimal agents (diazepam instead of magnesium continuation, oral labetalol for severe hypertension). Medical accuracy is excellent; management aligns with current eclampsia guidelines. No logical flaws; single best answer clearly supported. Minimal fix: None needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 36-week pregnant woman with eclampsia (seizure in setting of preeclampsia with severe features: BP 188/118, proteinuria, thrombocytopenia, elevated transaminases, hyperreflexia with clonus, visual symptoms). Key discriminating findings: breakthrough generalized tonic-clonic seizure despite 4-g magnesium loading dose, severe hypertension (188/118), and reassuring fetal status post-seizure. The clinical problem is managing eclampsia with breakthrough seizure and severe hypertension after initial magnesium. Option A correctly provides additional 2-g magnesium bolus (standard for breakthrough seizure on magnesium therapy) plus IV labetalol for acute severe hypertension control, aligning with ACOG guidelines. Option B (propofol, delay antihypertensives) inappropriately prioritizes neuroimaging over BP control. Option C incorrectly discontinues magnesium (first-line for eclampsia) and rushes to delivery before stabilization. Option D targets excessively low BP and inappropriately delays delivery 48 hours. Option E uses suboptimal agents (diazepam instead of magnesium continuation, oral labetalol for severe hypertension). Medical accuracy is excellent; management aligns with current eclampsia guidelines. No logical flaws; single best answer clearly supported. Minimal fix: None needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-006", "question": "A 9-year-old boy presents with 3 months of diffuse musculoskeletal pain, morning stiffness lasting 30-45 minutes, and profound fatigue. He was previously athletic but now avoids activity due to pain. Exam shows generalized tenderness over muscles and entheses, mild limitation of lumbar flexion, and no clear joint effusions. No rash, fevers, or weight loss. Labs: CBC, ESR, CRP, CK, aldolase, and TSH are normal. ANA 1:80 speckled, RF negative, HLA-B27 negative. XR of sacroiliac joints and spine are normal. He has fragmented sleep, difficulty focusing at school, and abdominal pain without alarm features. Which strategy is most appropriate to establish the correct diagnosis and direct management?", "options": ["Order whole-body MRI to evaluate for enthesitis-related arthritis or occult malignancy", "Diagnose juvenile fibromyalgia and implement a graded exercise and CBT program", "Perform lumbar puncture and brain MRI to evaluate for CNS vasculitis", "Start a 3-month trial of NSAIDs and low-dose prednisone for suspected JIA", "Order EMG and nerve conduction studies to exclude small fiber neuropathy"], "answer": "B", "answer_index": 1, "explanation": "Chronic widespread pain, normal inflammatory and muscle markers, non-restorative sleep, cognitive complaints, and functional GI symptoms are characteristic of juvenile fibromyalgia. Early diagnosis with emphasis on graded aerobic/strength exercise and cognitive behavioral therapy is key. Whole-body MRI, CNS workup, empiric steroids, or EMG are unnecessary and potentially harmful in this presentation.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 9-year-old with chronic widespread musculoskeletal pain (3 months), morning stiffness <1 hour, profound fatigue, sleep disturbance, cognitive difficulties, and functional GI symptoms—all with completely normal inflammatory markers (ESR, CRP), muscle enzymes (CK, aldolase), and imaging. The low-titer ANA (1:80) is non-specific and common in healthy children. Key discriminating findings: (1) diffuse pain without objective inflammation, (2) normal labs excluding inflammatory arthritis and myopathy, (3) sleep/cognitive/GI symptoms suggesting central sensitization, (4) functional impairment. This constellation strongly supports juvenile fibromyalgia. Option B correctly identifies the diagnosis and evidence-based management (graded exercise, CBT). Option A (whole-body MRI) is excessive given normal inflammatory markers and no red flags for malignancy. Option C (CNS workup) lacks neurologic signs. Option D (steroids for JIA) is contraindicated without synovitis or elevated inflammatory markers. Option E (EMG) is unwarranted without neuropathic features. The item is logically valid with a single defensible best answer matching the key. Medical accuracy is excellent—juvenile fibromyalgia diagnosis and non-pharmacologic management align with current pediatric rheumatology standards. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 9-year-old with chronic widespread musculoskeletal pain (3 months), morning stiffness <1 hour, profound fatigue, sleep disturbance, cognitive difficulties, and functional GI symptoms—all with completely normal inflammatory markers (ESR, CRP), muscle enzymes (CK, aldolase), and imaging. The low-titer ANA (1:80) is non-specific and common in healthy children. Key discriminating findings: (1) diffuse pain without objective inflammation, (2) normal labs excluding inflammatory arthritis and myopathy, (3) sleep/cognitive/GI symptoms suggesting central sensitization, (4) functional impairment. This constellation strongly supports juvenile fibromyalgia. Option B correctly identifies the diagnosis and evidence-based management (graded exercise, CBT). Option A (whole-body MRI) is excessive given normal inflammatory markers and no red flags for malignancy. Option C (CNS workup) lacks neurologic signs. Option D (steroids for JIA) is contraindicated without synovitis or elevated inflammatory markers. Option E (EMG) is unwarranted without neuropathic features. The item is logically valid with a single defensible best answer matching the key. Medical accuracy is excellent—juvenile fibromyalgia diagnosis and non-pharmacologic management align with current pediatric rheumatology standards. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-007", "question": "A 63-year-old woman with a 15-year history of seropositive rheumatoid arthritis (RA) presents with progressive dyspnea and dry cough over 4 months. Medications: methotrexate 20 mg weekly (for 10 years), low-dose prednisone 5 mg daily, and adalimumab for 3 years. She has no fevers or weight loss. Exam reveals bibasilar fine inspiratory crackles and mild digital clubbing. PFTs show FVC 62% predicted, FEV1/FVC 0.85, and DLCO 40% predicted. HRCT of the chest shows subpleural reticulation, traction bronchiectasis, and honeycombing predominantly in the bases, consistent with a usual interstitial pneumonia (UIP) pattern. There are no ground-glass opacities. Which is the most appropriate modification of her RA and lung disease management?", "options": ["Discontinue methotrexate permanently and increase adalimumab dose", "Continue current RA regimen and add nintedanib", "Stop adalimumab and switch to rituximab while continuing methotrexate", "Stop methotrexate and adalimumab, and start high-dose prednisone plus azathioprine", "Add mycophenolate mofetil to current regimen for treatment of ILD"], "answer": "B", "answer_index": 1, "explanation": "This is RA-associated ILD with a UIP pattern, which behaves like idiopathic pulmonary fibrosis and typically does not respond to high-dose immunosuppression. Nintedanib slows FVC decline in progressive fibrosing ILDs, including RA-ILD, and can be added while stable articular disease is controlled. Routine methotrexate cessation is not clearly beneficial here, and switching biologics or adding mycophenolate is more appropriate for inflammatory (e.g., NSIP) patterns rather than established fibrotic UIP.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 63-year-old woman with long-standing RA on methotrexate (10 years), prednisone, and adalimumab (3 years) presenting with progressive dyspnea. Key discriminating findings: HRCT shows UIP pattern (subpleural reticulation, traction bronchiectasis, honeycombing) without ground-glass opacities; severe restriction (FVC 62%, DLCO 40%); no acute inflammatory features. The clinical problem is managing RA-associated ILD with established fibrotic UIP pattern. Option B (continue current RA regimen, add nintedanib) is correct because: (1) UIP-pattern RA-ILD behaves like IPF and responds poorly to immunosuppression; (2) nintedanib is FDA-approved for progressive fibrosing ILD including RA-ILD; (3) her RA appears controlled (no mention of active synovitis), so current DMARD regimen should continue. Alternative assessment: A is incorrect (no clear benefit to stopping methotrexate in established fibrotic disease; increasing adalimumab unwarranted). C is incorrect (switching biologics without indication of RA flare or adalimumab failure). D is incorrect (high-dose steroids/azathioprine ineffective for fibrotic UIP, increases infection risk). E is incorrect (mycophenolate more appropriate for inflammatory NSIP pattern, not established UIP). Medical accuracy: Aligns with current guidelines on antifibrotic therapy for progressive fibrosing ILD. Minimal fix: None needed; item is logically valid and medically accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 63-year-old woman with long-standing RA on methotrexate (10 years), prednisone, and adalimumab (3 years) presenting with progressive dyspnea. Key discriminating findings: HRCT shows UIP pattern (subpleural reticulation, traction bronchiectasis, honeycombing) without ground-glass opacities; severe restriction (FVC 62%, DLCO 40%); no acute inflammatory features. The clinical problem is managing RA-associated ILD with established fibrotic UIP pattern. Option B (continue current RA regimen, add nintedanib) is correct because: (1) UIP-pattern RA-ILD behaves like IPF and responds poorly to immunosuppression; (2) nintedanib is FDA-approved for progressive fibrosing ILD including RA-ILD; (3) her RA appears controlled (no mention of active synovitis), so current DMARD regimen should continue. Alternative assessment: A is incorrect (no clear benefit to stopping methotrexate in established fibrotic disease; increasing adalimumab unwarranted). C is incorrect (switching biologics without indication of RA flare or adalimumab failure). D is incorrect (high-dose steroids/azathioprine ineffective for fibrotic UIP, increases infection risk). E is incorrect (mycophenolate more appropriate for inflammatory NSIP pattern, not established UIP). Medical accuracy: Aligns with current guidelines on antifibrotic therapy for progressive fibrosing ILD. Minimal fix: None needed; item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-008", "question": "A 45-year-old man with poorly controlled type 2 diabetes (A1c 10.8%), BMI 36 kg/m², and mild nonproliferative diabetic retinopathy presents for follow-up. Medications: metformin 1000 mg BID and basal insulin glargine 35 units nightly. He had an episode of acute pancreatitis 3 years ago attributed to severe hypertriglyceridemia (TG 1,800 mg/dL); since then, triglycerides have been controlled around 250-300 mg/dL on fenofibrate. He drinks no alcohol. eGFR is 65 mL/min/1.73 m², AST/ALT are mildly elevated (1.5× ULN), and ultrasound shows fatty liver without biliary disease. He is interested in newer injectable therapies for weight loss and glucose control. Which glucose-lowering agent is most appropriate to add now?", "options": ["Liraglutide", "Semaglutide", "Dulaglutide", "Tirzepatide", "Empagliflozin"], "answer": "E", "answer_index": 4, "explanation": "Given prior pancreatitis, any incretin-based therapy (GLP-1 receptor agonists and dual GIP/GLP-1 agonists like tirzepatide) carries a theoretical risk of recurrence, and product labels recommend caution or avoidance. An SGLT2 inhibitor such as empagliflozin improves glycemic control, promotes modest weight loss, and provides CV/renal benefits without known pancreatitis signal. His eGFR is adequate, making empagliflozin the safest choice among the listed options.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a GLP-1 RA is the better answer. The stem describes a patient with poorly controlled T2DM (A1c 10.8%), obesity (BMI 36), and history of acute pancreatitis 3 years ago (now resolved, triglycerides controlled). Key discriminating findings: severe hyperglycemia requiring intensification, obesity with weight loss interest, prior pancreatitis episode attributed to hypertriglyceridemia (not recurrent), mild NAFLD, adequate eGFR 65. The question asks for the most appropriate agent to add. Main logical issue: The rationale invokes 'theoretical risk' and 'caution' from GLP-1 RA labels regarding pancreatitis history, but current evidence shows no causal link between GLP-1 RAs and pancreatitis; the association is confounded by obesity/diabetes. Major guidelines (ADA 2024, AACE) do NOT contraindicate GLP-1 RAs in patients with remote pancreatitis, especially when the etiology (hypertriglyceridemia) is now controlled. Given the patient's severe hyperglycemia (A1c 10.8%) and explicit interest in weight loss, a high-efficacy GLP-1 RA (semaglutide or tirzepatide) is medically superior to empagliflozin, which offers modest glycemic reduction (0.5-0.8% A1c) and minimal weight loss (2-3 kg). The keyed answer (empagliflozin) is overly conservative and not the single best choice. Minimal fix: Remove history of pancreatitis or specify recurrent/idiopathic pancreatitis to justify GLP-1 RA avoidance.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a GLP-1 RA is the better answer. The stem describes a patient with poorly controlled T2DM (A1c 10.8%), obesity (BMI 36), and history of acute pancreatitis 3 years ago (now resolved, triglycerides controlled). Key discriminating findings: severe hyperglycemia requiring intensification, obesity with weight loss interest, prior pancreatitis episode attributed to hypertriglyceridemia (not recurrent), mild NAFLD, adequate eGFR 65. The question asks for the most appropriate agent to add. Main logical issue: The rationale invokes 'theoretical risk' and 'caution' from GLP-1 RA labels regarding pancreatitis history, but current evidence shows no causal link between GLP-1 RAs and pancreatitis; the association is confounded by obesity/diabetes. Major guidelines (ADA 2024, AACE) do NOT contraindicate GLP-1 RAs in patients with remote pancreatitis, especially when the etiology (hypertriglyceridemia) is now controlled. Given the patient's severe hyperglycemia (A1c 10.8%) and explicit interest in weight loss, a high-efficacy GLP-1 RA (semaglutide or tirzepatide) is medically superior to empagliflozin, which offers modest glycemic reduction (0.5-0.8% A1c) and minimal weight loss (2-3 kg). The keyed answer (empagliflozin) is overly conservative and not the single best choice. Minimal fix: Remove history of pancreatitis or specify recurrent/idiopathic pancreatitis to justify GLP-1 RA avoidance.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-009", "question": "A 27-year-old woman is brought to the ED after collapsing during a 10-km race. Bystanders report sudden loss of consciousness without seizure activity; CPR was started immediately, and an AED delivered one shock for ventricular fibrillation with ROSC. She is now awake and oriented. No drugs or supplements; family history notable for an uncle who died suddenly at 32 while swimming, presumed drowning. Vitals: HR 78/min, BP 112/68 mm Hg, normal exam. Labs and echocardiogram are normal. Baseline ECG shows QTc 460 ms, normal QRS, and normal ST-T waves. During recovery from an exercise treadmill test, she develops polymorphic VT that terminates spontaneously; QTc in recovery is 510 ms with late-appearing T waves in V2-V4. Which is the most appropriate next step in management?", "options": ["Implant an ICD and start high-dose beta-blocker therapy", "Start nadolol and schedule left cardiac sympathetic denervation", "Start flecainide in addition to beta-blocker therapy", "Begin verapamil and restrict participation to low-intensity sports", "Perform genetic testing for catecholaminergic polymorphic VT before any therapy"], "answer": "A", "answer_index": 0, "explanation": "This presentation is consistent with congenital long QT syndrome (likely LQT1 or LQT2) with exercise-associated VF arrest and marked QT prolongation in recovery. Survivors of cardiac arrest from LQTS require ICD plus beta-blocker therapy. LCSD or flecainide may be adjuncts in selected cases but not first-line over ICD after arrest. Verapamil is ineffective, and genetic testing should not delay life-saving therapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 27-year-old woman with aborted sudden cardiac death (VF arrest during exercise), family history of sudden death, baseline QTc 460 ms, and exercise-induced polymorphic VT with marked QTc prolongation to 510 ms during recovery with late T-wave appearance. These findings strongly suggest congenital long QT syndrome (LQTS), likely LQT1 given exercise trigger. Key discriminating findings: (1) survived cardiac arrest from VF, (2) documented exercise-induced polymorphic VT, (3) QT prolongation especially in recovery, (4) positive family history. For LQTS patients who survive cardiac arrest, guidelines mandate ICD implantation (secondary prevention) plus beta-blocker therapy as first-line management. Option A correctly combines both. Option B (LCSD) is adjunctive therapy for refractory cases, not first-line. Option C (flecainide) is used for specific LQTS subtypes (LQT3) but not standard post-arrest. Option D (verapamil) is ineffective in LQTS. Option E delays life-saving therapy; genetic testing should not precede ICD in arrest survivors. The item is medically accurate, logically sound, and the key is appropriately supported. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 27-year-old woman with aborted sudden cardiac death (VF arrest during exercise), family history of sudden death, baseline QTc 460 ms, and exercise-induced polymorphic VT with marked QTc prolongation to 510 ms during recovery with late T-wave appearance. These findings strongly suggest congenital long QT syndrome (LQTS), likely LQT1 given exercise trigger. Key discriminating findings: (1) survived cardiac arrest from VF, (2) documented exercise-induced polymorphic VT, (3) QT prolongation especially in recovery, (4) positive family history. For LQTS patients who survive cardiac arrest, guidelines mandate ICD implantation (secondary prevention) plus beta-blocker therapy as first-line management. Option A correctly combines both. Option B (LCSD) is adjunctive therapy for refractory cases, not first-line. Option C (flecainide) is used for specific LQTS subtypes (LQT3) but not standard post-arrest. Option D (verapamil) is ineffective in LQTS. Option E delays life-saving therapy; genetic testing should not precede ICD in arrest survivors. The item is medically accurate, logically sound, and the key is appropriately supported. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-010", "question": "A 7-year-old boy with sickle cell disease (HbSS) presents with acute onset of severe left hip pain and inability to bear weight. He had a pain crisis 2 weeks ago treated with IV opioids and hydration. Temperature is 38.3°C, HR 120/min, BP 96/58 mm Hg. Hip exam reveals extreme pain with any passive motion, especially internal rotation, and the leg is slightly flexed and externally rotated. WBC 18,000/µL, CRP 14 mg/dL, ESR 86 mm/h. Plain radiograph is unremarkable. MRI of the pelvis obtained within 6 hours of symptom onset shows bone marrow edema of the femoral head and neck with a moderate hip joint effusion, but no definite abscess or cortical destruction. Which is the most appropriate next step?", "options": ["Treat as vaso-occlusive crisis with IV opioids and observe for 24-48 hours", "Start broad-spectrum IV antibiotics and schedule urgent surgical hip drainage", "Obtain radionuclide bone scan to differentiate infarction from osteomyelitis", "Repeat pelvic MRI with contrast in 72 hours before deciding on surgery", "Start IV antibiotics and aspirate the hip joint under ultrasound guidance"], "answer": "E", "answer_index": 4, "explanation": "In children with sickle cell disease, distinguishing osteomyelitis/septic arthritis from bone infarction is challenging; fever, high inflammatory markers, inability to bear weight, and effusion demand prompt evaluation. Joint aspiration with culture, ideally under ultrasound guidance, plus empiric IV antibiotics is the appropriate next step to diagnose or exclude septic arthritis early. Delaying for observation or repeat imaging risks joint destruction; bone scan is nonspecific in this setting, and immediate surgical drainage without diagnostic aspiration may be premature without frank clinical sepsis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 7-year-old with sickle cell disease presenting with acute hip pain, fever (38.3°C), inability to bear weight, elevated inflammatory markers (WBC 18,000, CRP 14, ESR 86), and MRI showing joint effusion without abscess. The clinical problem is distinguishing septic arthritis from vaso-occlusive crisis/bone infarction—a classic diagnostic challenge in sickle cell patients. Key discriminating findings: fever, extreme pain with passive motion (especially internal rotation), externally rotated/flexed leg position (classic septic hip posture), significant effusion, and markedly elevated inflammatory markers. These findings strongly suggest septic arthritis requiring urgent diagnosis. Option E (IV antibiotics + joint aspiration under ultrasound) is the standard approach: empiric antibiotics cover infection risk while aspiration provides definitive diagnosis via synovial fluid analysis and culture. Option A (observation) risks irreversible joint damage if septic. Option B (surgical drainage without aspiration) is premature without confirming purulent fluid. Option C (bone scan) is nonspecific and delays treatment. Option D (repeat MRI in 72 hours) unacceptably delays diagnosis. The keyed answer aligns with current pediatric infectious disease and orthopedic guidelines for suspected pediatric septic arthritis in high-risk populations. Medical accuracy is excellent; the clinical presentation, diagnostic approach, and management are standard-of-care. No logical flaws or missing critical details prevent unique best-answer selection.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 7-year-old with sickle cell disease presenting with acute hip pain, fever (38.3°C), inability to bear weight, elevated inflammatory markers (WBC 18,000, CRP 14, ESR 86), and MRI showing joint effusion without abscess. The clinical problem is distinguishing septic arthritis from vaso-occlusive crisis/bone infarction—a classic diagnostic challenge in sickle cell patients. Key discriminating findings: fever, extreme pain with passive motion (especially internal rotation), externally rotated/flexed leg position (classic septic hip posture), significant effusion, and markedly elevated inflammatory markers. These findings strongly suggest septic arthritis requiring urgent diagnosis. Option E (IV antibiotics + joint aspiration under ultrasound) is the standard approach: empiric antibiotics cover infection risk while aspiration provides definitive diagnosis via synovial fluid analysis and culture. Option A (observation) risks irreversible joint damage if septic. Option B (surgical drainage without aspiration) is premature without confirming purulent fluid. Option C (bone scan) is nonspecific and delays treatment. Option D (repeat MRI in 72 hours) unacceptably delays diagnosis. The keyed answer aligns with current pediatric infectious disease and orthopedic guidelines for suspected pediatric septic arthritis in high-risk populations. Medical accuracy is excellent; the clinical presentation, diagnostic approach, and management are standard-of-care. No logical flaws or missing critical details prevent unique best-answer selection.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]